comparemela.com

Latest Breaking News On - Transcription modulator - Page 5 : comparemela.com

Moleculin to Participate in the Virtual Investor Ask the CEO Conference

Live video webcast with Walter Klemp, CEO and Jonathan Foster, Executive VP and CFO of Moleculin on Tuesday, October 25th at 12:00 PM ET HOUSTON, Oct. 11, 2023 /PRNewswire/ Moleculin Biotech,.

United statesJonathan fosterWalter klempJenene thomasPrnewswire moleculin biotech incMoleculin biotech incChief executive officerChief financial officerVirtual investor askMoleculin biotechTranscription modulator

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

– Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33% – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML HOUSTON, Oct..

United statesJenene thomasWalter klempSecurities exchangeMoleculin biotech incDrug administrationCompany phaseExchange commissionFast track statusOrphan drug designationMoleculin biotechChief executive officerTranscription modulatorSecurities actSecurities exchange actPrivate securities litigation reform act

Moleculin Announces Completion of Enrollment in U S Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including.

United statesJenene thomasWalter klempExchange commissionEastern cooperative oncology groupPrnewswire moleculin biotech incSecurities exchangeCompany us phaseConnective tissue oncology society annual meetingDrug administrationMoleculin biotech incFast track statusOrphan drug designationChief executive officerConnective tissue oncology societyAnnual meeting

Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

– Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Company s Annamycin clinical trials – Next generation anthracycline,.

United statesWalter klempJenene thomasPrnewswire moleculin biotech incExchange commissionCompany annamycinMoleculin biotech incSecurities exchangeRecommended phaseChief executive officerMoleculin biotechTranscription modulatorSecurities actSecurities exchange actPrivate securities litigation reform actAlthough moleculin

Moleculin Reports Second Quarter 2023 Financial Results

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,.

United kingdomUnited statesLiposomal annamycinWalter klempJenene thomasExchange commissionMoleculin biotech incPrnewswire moleculin biotech incSecurities exchangeShareholder intelligence servicesBritish journal of cancer researchReleased clinical trial updateChief executive officerMoleculin provides updateOngoing clinical trialsOutlines expected upcoming milestones

vimarsana © 2020. All Rights Reserved.